[Tiagabine--own experience in the refractory epilepsy treatment]

Area of Science:

• Pharmacology
• Neurology

Background:

• Tiagabine represents a novel class of antiepileptic drugs.
• It possesses a distinct mechanism of action.
• Its pharmacokinetic profile is favorable, with good gastrointestinal absorption and linear kinetics.

Purpose of the Study:

• To evaluate the efficacy and place of tiagabine in epilepsy treatment.
• To highlight its utility in managing partial seizures.
• To re-evaluate its role in drug-resistant epilepsy.

Main Methods:

• Review of existing literature and clinical studies on tiagabine.
• Analysis of tiagabine's pharmacokinetic and pharmacodynamic properties.
• Assessment of its interaction profile with other antiepileptic drugs.

Main Results:

• Tiagabine demonstrates good oral bioavailability and linear pharmacokinetics.
• It exhibits minimal impact on cognitive functions.
• It shows limited interactions with other antiepileptic medications.
• Effective for partial seizures with or without secondary generalization in patients aged 12+.

Conclusions:

• Tiagabine is a well-tolerated antiepileptic drug with a unique mechanism.
• It is suitable for adults and children over 12 with partial seizures.
• Current literature and studies suggest tiagabine remains an important therapeutic option for drug-resistant epilepsy, despite being underutilized.